AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)
Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%
AbbVie operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
AbbVie's operating income for the twelve months ending Jun 30, 2026 was $16.87B, up 53.8% year over year. For fiscal 2025 it was $15.08B, up 65.0% from the year before. Over ten years it grew 7.2% a year on average. The highest annual figure on record is $18.12B in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.08B | +65.0% |
| FY2024 | Dec 31, 2024 | $9.14B | -28.4% |
| FY2023 | Dec 31, 2023 | $12.76B | -29.6% |
| FY2022 | Dec 31, 2022 | $18.12B | +1.1% |
| FY2021 | Dec 31, 2021 | $17.92B | +57.7% |
| FY2020 | Dec 31, 2020 | $11.36B | -12.5% |
| FY2019 | Dec 31, 2019 | $12.98B | +103.4% |
| FY2018 | Dec 31, 2018 | $6.38B | -33.1% |
| FY2017 | Dec 31, 2017 | $9.55B | +2.2% |
| FY2016 | Dec 31, 2016 | $9.34B | +23.9% |
| FY2015 | Dec 31, 2015 | $7.54B | +121.0% |
| FY2014 | Dec 31, 2014 | $3.41B | -39.8% |
| FY2013 | Dec 31, 2013 | $5.66B | -2.6% |
| FY2012 | Dec 31, 2012 | $5.82B | +60.7% |
| FY2011 | Dec 31, 2011 | $3.62B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $6.43B | +31.4% |
| Q1 FY2026 | Mar 31, 2026 | $3.99B | +6.9% |
| Q4 FY2025 | Dec 31, 2025 | $4.54B | – |
| Q3 FY2025 | Sep 30, 2025 | $1.90B | -50.3% |
| Q2 FY2025 | Jun 30, 2025 | $4.89B | +22.4% |
| Q1 FY2025 | Mar 31, 2025 | $3.73B | +33.4% |
| Q4 FY2024 | Dec 31, 2024 | -$1.49B | -146.6% |
| Q3 FY2024 | Sep 30, 2024 | $3.83B | +68.0% |
| Q2 FY2024 | Jun 30, 2024 | $4.00B | -11.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.80B | +1.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.20B | -41.9% |
| Q3 FY2023 | Sep 30, 2023 | $2.28B | -50.4% |
| Q2 FY2023 | Jun 30, 2023 | $4.51B | +37.0% |
| Q1 FY2023 | Mar 31, 2023 | $2.77B | -41.3% |
| Q4 FY2022 | Dec 31, 2022 | $5.50B | +8.4% |
| Q3 FY2022 | Sep 30, 2022 | $4.60B | +6.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.30B | -25.8% |
| Q1 FY2022 | Mar 31, 2022 | $4.72B | +15.0% |
| Q4 FY2021 | Dec 31, 2021 | $5.07B | +35.2% |
| Q3 FY2021 | Sep 30, 2021 | $4.31B | +32.3% |
| Q2 FY2021 | Jun 30, 2021 | $4.44B | +490.6% |
| Q1 FY2021 | Mar 31, 2021 | $4.10B | +13.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.75B | -5.1% |
| Q3 FY2020 | Sep 30, 2020 | $3.26B | +24.4% |
| Q2 FY2020 | Jun 30, 2020 | $752.00M | -77.9% |
| Q1 FY2020 | Mar 31, 2020 | $3.60B | +19.7% |
| Q4 FY2019 | Dec 31, 2019 | $3.96B | – |
| Q3 FY2019 | Sep 30, 2019 | $2.62B | -17.2% |
| Q2 FY2019 | Jun 30, 2019 | $3.40B | +23.1% |
| Q1 FY2019 | Mar 31, 2019 | $3.01B | +3.7% |
| Q4 FY2018 | Dec 31, 2018 | -$2.44B | -237.0% |
| Q3 FY2018 | Sep 30, 2018 | $3.16B | +17.3% |
| Q2 FY2018 | Jun 30, 2018 | $2.76B | +3.8% |
| Q1 FY2018 | Mar 31, 2018 | $2.90B | +20.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.78B | -23.0% |
| Q3 FY2017 | Sep 30, 2017 | $2.69B | +14.1% |
| Q2 FY2017 | Jun 30, 2017 | $2.66B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.41B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.31B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.36B | – |
See a number that looks wrong?